A sequencing-derived inflammation score is a vendor-computed index that estimates inflammatory tone from microbiome features, low butyrate producers, Proteobacteria enrichment, predicted LPS pathways, or distance from a “non-inflammatory” reference profile. It is not fecal calprotectin, lactoferrin, or CRP, and it does not measure neutrophil influx into the gut lumen.
A surprising but common pattern is a high inflammation score alongside normal calprotectin, that often reflects algorithm design and taxon proxies, not mucosal inflammation equivalent to IBD activity. For marker tiering and clinical routing, see Gut inflammation markers.
How this differs from calprotectin
| Feature | Sequencing inflammation score | Fecal calprotectin |
|---|---|---|
| Source | Metagenomic/16S inference | Direct protein assay in stool |
| Reflects | Composition correlates of inflammation in cohorts | Neutrophil activity in intestinal lumen |
| Clinical validation | Vendor-specific; often undisclosed | Guideline-backed in IBD pathways |
| IBD monitoring | Not standard of care | Standard adjunct (Calprotectin) |
| Functional IBS | May flag without mucosal neutrophilia | Usually normal |
Low Faecalibacterium prausnitzii associates with IBD in research cohorts (Sokol et al., 2008), and vendors sometimes fold such taxa into inflammation indexes. In an individual, low F. prausnitzii also follows antibiotics, low fiber, and method noise, it is not a one-to-one inflammation readout.
When symptoms suggest inflammatory bowel disease, persistent bloody diarrhoea, weight loss, nocturnal stools, calprotectin and referral precede reinterpretation of a sequencing score.
How vendors typically build the score
Published pipelines vary; common inputs include:
| Input feature | Rationale in research | Individual-level limit |
|---|---|---|
| ↓ Butyrate producers (Faecalibacterium, Roseburia) | Associated with IBD remission/activity in cohorts | Diet and antibiotics shift abundance |
| ↑ Proteobacteria / Enterobacteriaceae | Bloom signal in dysbiosis literature | Transient after antibiotics |
| Predicted LPS biosynthesis | Endotoxin hypotheses in metabolic research | Pathway prediction ≠ measured LPS |
| Distance from “healthy” metagenome | Machine-learning classifiers in studies | Overfits reference population |
Scores are calibrated on training cohorts that may not match your geography, diet, or comorbidities. Cross-vendor scores are not comparable.
Validation status
Peer-reviewed IBD microbiome signatures exist at the population level (see reading list), but consumer panel indexes rarely publish:
- Sensitivity/specificity vs calprotectin or histology
- Performance in IBS vs IBD discrimination
- Longitudinal response to anti-inflammatory treatment
Until a vendor provides independent validation data, treat the score as exploratory context, tier below Gut inflammation markers and far below endoscopy when alarm features exist.
Research classifiers can achieve moderate AUC for IBD vs controls in combined cohorts, but translation to a home kit flag without disclosed metrics is a different evidentiary step.
When to trust clinical biomarkers instead
| Clinical question | Trust first |
|---|---|
| Is there neutrophilic intestinal inflammation? | Fecal calprotectin / lactoferrin |
| Is IBD activity changing on treatment? | Calprotectin, symptoms, endoscopy, not sequencing index |
| Is there systemic inflammation? | CRP, clinical assessment |
| Does microbiome composition associate with inflammation in literature? | Cohort metagenomics, association only |
Normal sequencing inflammation score does not exclude IBD. Elevated score does not replace colonoscopy when red flags are present.
For reconciling a high inflammation index with normal calprotectin and low diversity: Multi-marker synthesis.
High vs low on reports
| Report flag | May indicate (weakly) | Does not establish |
|---|---|---|
| High inflammation score | Profile resembles inflammatory cohorts in vendor database | Active IBD flare; need for biologics |
| Low score | Proximity to vendor “non-inflammatory” reference | Absence of all immune activation |
| Improving score on retest | Composition shifted toward reference | Mucosal healing without calprotectin/symptoms |
Always document antibiotics, diet change, and assay version when comparing scores over time (Retesting over time).
What not to conclude from sequencing inflammation scores
| If the report says… | Do not conclude… |
|---|---|
| High inflammation index | Same as raised calprotectin |
| Low Faecalibacterium driving high score | Proven colonic inflammation |
| Low inflammation score | IBD ruled out |
| Score improved after probiotic | Histologic or calprotectin remission |
| High score + IBS symptoms | Antibiotics or anti-inflammatory diet indicated without clinician |
Related pages
- Reading your microbiome report, hub for report lines
- Gut inflammation markers, marker tiering and routing
- Calprotectin, validated fecal inflammatory protein
- Faecalibacterium prausnitzii, taxon often embedded in scores
- Opportunistic bacteria, Proteobacteria bloom context
- Red flags, urgent symptoms
- Multi-marker synthesis, conflicting narratives